{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FluMist&page=15",
    "query": {
      "intervention": "FluMist",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 1159,
    "total_pages": 116,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FluMist&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FluMist&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T14:48:40.309Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01059617",
      "title": "Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' FluLaval®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "19 Years to 40 Years"
      },
      "enrollment_count": 133,
      "start_date": "2010-02-09",
      "completion_date": "2011-10-21",
      "has_results": true,
      "last_update_posted_date": "2018-08-20",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 3,
      "location_summary": "Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Milford",
          "state": "Massachusetts"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059617"
    },
    {
      "nct_id": "NCT05422326",
      "title": "A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human",
        "Influenza in Birds",
        "Respiratory Tract Infections",
        "Infections",
        "Orthomyxoviridae Infections",
        "RNA Virus Infections",
        "Virus Diseases",
        "Respiratory Tract Diseases"
      ],
      "interventions": [
        {
          "name": "aH5N6c on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N6c on Day 22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo on Day 22",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2022-07-18",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 18,
      "location_summary": "Huntsville, Alabama • Tempe, Arizona • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422326"
    },
    {
      "nct_id": "NCT07111078",
      "title": "Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza Prevention",
        "Pandemic Influenza Prevention"
      ],
      "interventions": [
        {
          "name": "VRC-FLUMOS0122-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALFQ",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2025-08-27",
      "completion_date": "2027-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07111078"
    },
    {
      "nct_id": "NCT00304434",
      "title": "Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "Probenecid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2005-02",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2009-09-23",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304434"
    },
    {
      "nct_id": "NCT02469298",
      "title": "Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Virus Diseases"
      ],
      "interventions": [
        {
          "name": "GSK1325756 (Danirixin)",
          "type": "DRUG"
        },
        {
          "name": "Placebo To Match GSK1325756",
          "type": "DRUG"
        },
        {
          "name": "Oseltamivir Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo To Match Oseltamivir Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 45,
      "start_date": "2015-06-01",
      "completion_date": "2016-04-25",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 5,
      "location_summary": "Palmetto Bay, Florida • Blackfoot, Idaho • Oklahoma City, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Blackfoot",
          "state": "Idaho"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02469298"
    },
    {
      "nct_id": "NCT05493787",
      "title": "Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Reminder",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Geisinger Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139503,
      "start_date": "2022-11-08",
      "completion_date": "2023-01-03",
      "has_results": true,
      "last_update_posted_date": "2024-12-30",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 1,
      "location_summary": "Danville, Pennsylvania",
      "locations": [
        {
          "city": "Danville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05493787"
    },
    {
      "nct_id": "NCT00988143",
      "title": "A Study of Influenza Virus Vaccines in Children and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "2009-2010 Trivalent Influenza Virus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2008-2009 Trivalent Influenza Virus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Virus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 600,
      "start_date": "2009-10",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2013-12-12",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 4,
      "location_summary": "Durham, North Carolina • Cincinnati, Ohio • Jefferson Hills, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Jefferson Hills",
          "state": "Pennsylvania"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00988143"
    },
    {
      "nct_id": "NCT02572817",
      "title": "Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza A Virus Infection"
      ],
      "interventions": [
        {
          "name": "High-titer anti-influenza plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low-titer anti-influenza plasma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Weeks and older"
      },
      "enrollment_count": 138,
      "start_date": "2015-11",
      "completion_date": "2018-05-18",
      "has_results": true,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 30,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02572817"
    },
    {
      "nct_id": "NCT00192218",
      "title": "Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "FluMist",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 3022,
      "start_date": "2004-10",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2008-09-22",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Seattle, Washington",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00192218"
    },
    {
      "nct_id": "NCT01406418",
      "title": "Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "CR6261 2 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CR6261 5 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CR6261 15 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CR6261 30 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CR6261 50 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-02",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-12-19",
      "last_synced_at": "2026-10-19T14:48:40.309Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01406418"
    }
  ]
}